GlobeNewswire by notified

Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Share


Ad hoc announcement pursuant to Art. 53 LR

Pratteln, Switzerland, and Rockville, MD, USA,January 9, 2023 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for vamorolonefor the treatment of Duchenne muscular dystrophy (DMD) for filing. The FDA has set October26, 2023, as the Prescription Drug User Fee Act (PDUFA) target action date.

The PDUFA date is the target date for the FDA to complete its review of the NDA. Furthermore, the FDA stated that it does not currently plan to hold an advisory committee meeting to discuss the application. Subject to approval, Santhera plans to launch vamorolone in the U.S. in Q4-2023.

“We are delighted that the FDA has accepted Santhera’s vamorolone NDA for filing. We believe this product addresses a clear unmet medical need and for Santhera, this represents the achievement of an important milestone with key significance for our future success,” said Dario Eklund, CEO of Santhera. “We look forward to working closely with U.S. regulators to advance vamorolone towards approval.”

“This is an exciting time for the Duchenne community as the data generated across the clinical trial program indicate that vamorolone has the potential to address relevant aspects in patient care that could also enhance treatment outcomes,” said Eric Hoffman, PhD, President and CEO of ReveraGen BioPharma. “If approved, vamorolone will emerge as an additional treatment option in current standards of care in DMD, with the potential to address unmet medical needs and treat a majority of Duchenne patients starting at an early age.”

The NDA submission for vamorolone was supported by clinical data from the positive pivotal Phase 2b VISION-DMD study which met the primary endpoint with statistical significance over placebo [1]. The data package also included data from four open-label studies (including extension) in which vamorolone was administered at doses between 2 and 6 mg/kg/day for a total treatment period of up to 30 months [2].

In Europe, a marketing authorization application (MAA), seeking approval for vamorolone in the European Union, has been validated and is under review by the European Medicines Agency (EMA).

Vamorolone has been granted Orphan Drug status in the U.S. and in Europe for DMD, and has received Fast Track and Rare Pediatric Disease designations by the U.S. FDA and Promising Innovative Medicine (PIM) status from the UK MHRA for DMD.

About Vamorolone
Vamorolone is an investigational drug candidate with a mode of action based on binding to the same receptor as corticosteroids but modifying its downstream activity and as such is considered a dissociative anti-inflammatory drug [2-5]. This mechanism has shown the potential to ‘dissociate’ efficacy from steroid safety concerns and therefore vamorolone could emerge as an alternative to existing corticosteroids, the current standard of care in children and adolescent subjects with DMD. In the pivotal VISION-DMD study, vamorolone met the primary endpoint Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability profile [1]. The most commonly reported adverse events versus placebo from the VISION-DMD study were cushingoid features, vomiting and vitamin D deficiency. Adverse events were generally of mild to moderate severity. Vamorolone is an investigational medicine and is currently not approved for use by any health authority.

References:
[1]         Guglieri M et al (2022). JAMA Neurol. Published online August 29, 2022. doi:10.1001/jamaneurol.2022.2480. Link.
[2]        Mah JK et al (2022). JAMA Netw Open. 2022;5(1):e2144178. doi:10.1001/jamanetworkopen.2021.44178. Link.
[3]         Guglieri, et al (2022) JAMA. doi:10.1001/jama.2022.4315
[4]         Heier CR at al (2019). Life Science Alliance DOI: 10.26508
[5]         Liu X, et al (2020). Proc Natl Acad Sci USA 117:24285-24293

About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a rare inherited X-chromosome-linked disease, which almost exclusively affects males. DMD is characterized by inflammation which is present at birth or shortly thereafter. Inflammation leads to fibrosis of muscle and is clinically manifested by progressive muscle degeneration and weakness. Major milestones in the disease are the loss of ambulation, the loss of self-feeding, the start of assisted ventilation, and the development of cardiomyopathy. DMD reduces life expectancy to before the fourth decade due to respiratory and/or cardiac failure. Corticosteroids are the current standard of care for the treatment of DMD.

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. The Company has an exclusive license for all indications worldwide to vamorolone, a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy as an alternative to standard corticosteroids. Santhera has a new drug application (NDA) under review by the U.S. FDA and a marketing authorization application (MAA) under review by the European Medicines Agency (EMA) for vamorolone for the treatment of DMD. The clinical stage pipeline also includes lonodelestat to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases. Santhera out-licensed rights to its first approved product, Raxone® (idebenone), outside North America and France for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com.

Raxone® is a trademark of Santhera Pharmaceuticals.

About ReveraGen BioPharma
ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders. The development of ReveraGen’s lead compound, vamorolone, has been supported through partnerships with foundations worldwide, including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation to Eradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryan’s Quest, Alex’s Wish, DuchenneUK, Pietro’s Fight, Michael’s Cause, Duchenne Research Fund, and Defeat Duchenne Canada. ReveraGen has also received generous support from the US Department of Defense CDMRP, National Institutes of Health (NCATS, NINDS, NIAMS), and European Commission (Horizons 2020). www.reveragen.com

For further information please contact:
Santhera
Santhera Pharmaceuticals Holding AG, Hohenrainstrasse 24, CH-4133 Pratteln
public-relations@santhera.com or
Eva Kalias, Head Investor Relations & Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
ReveraGen BioPharma
Eric Hoffman, PhD, President and CEO
Phone: + 1 240-672-0295
eric.hoffman@reveragen.com

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ULTRA Abu Dhabi Drops Stacked Phase One Lineup31.1.2023 23:00:00 CET | Press release

AFROJACK, CALVIN HARRIS, ILLENIUM, NERVO, NGHTMRE, SKRILLEX to headline the Main Stage. ADAM BEYER, AMELIE LENS, SASHA & JOHN DIGWEED to lead Resistance. ULTRA Abu Dhabi to be held at ETIHAD PARK, YAS ISLAND, ABU DHABI on SATURDAY 4 & SUNDAY 5 MARCH 2023. SEOUL, South Korea, Jan. 31, 2023 (GLOBE NEWSWIRE) -- UC Global, the regional partner of ULTRA Worldwide in the United Arab Emirates and the local organizer of ULTRA Abu Dhabi, has announced the first wave of headliners set to play its inaugural edition Saturday 4 and Sunday 5 March 2023. Ever since the announcement that ULTRA Worldwide would be headed to the Middle East for the very first time, anticipation has reached a fever pitch as to which artists would be coming to the region. Now, the wait is finally over as the festival's stellar Phase One lineup has been revealed. Multi-award-winning and platinum-record-selling artist Afrojack is no stranger to the ULTRA main stage and will be on hand to deliver yet another high-octane set.

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK31.1.2023 22:30:00 CET | Press release

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick NT-proBNP test currently commercially available.The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay that can aid in the diagnosis of congestive heart failure (CHF).Available on the same point of care (POC) Platform as LumiraDx’s high sensitivity SARS-CoV-2 antigen, HbA1c, D-Dimer, INR, CRP, Flu A/B, RSV, SARS-CoV-2 antibody, SARS-CoV-2 antigen pool, SARS-CoV-2 Ag Ultra and Ultra Pool tests.*LumiraDx is partnering with Medtronic and a number of local healthcare trusts and charities in the UK to launch the Your Heart Matters Bus initiative where members of the public will be offered free heart health checks, LumiraDx NT-proBNP test results as indicated and medical information through a mobile walk-on service. LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE

International Petroleum Corporation Updated Share Capital31.1.2023 21:30:00 CET | Press release

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO)reports the following, in accordance with the Swedish Financial Instruments Trading Act: Following the cancellation of738,243 common shares repurchased by IPC under the share repurchase program,the total number of issued and outstanding common shares of the Corporation is 136,089,756 common shares with voting rights as atJanuary 31, 2023, of which IPC holds71,416 common shares in treasury. International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol "IPCO". For further information, please contact: Rebecca Gordon VP Corporate

Nokia Corporation: Repurchase of own shares on 31.01.202331.1.2023 20:00:00 CET | Press release

Nokia Corporation Stock Exchange Release 31 January 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 31.01.2023 Espoo, Finland – On 31 January 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL261,4854.33CEUX19,9384.34AQEU23,7644.33TQEX12,8134.34Total318,0004.33 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 20